Proceedings of Two Satellite Symposia Held at EuroPCR in May 2015 in Paris
The use of second-generation polymeric metallic drug-eluting stents (DES) in percutaneous coronary intervention (PCI) is now routine practice and has demonstrated excellent safety and efficacy compared with first-generation DES. These stents have enhanced PCI procedures, enabling the treatment of more complex lesions and clinical cases. However, specific patient subsets still require procedural and/or technological refinement to further enhance success rates and longterm patient-centred clinical outcomes. Two symposia at EuroPCR in May 2015 in Paris focused on how polymer-free DES may increase safety in PCI requiring short duration of dual antiplatelet therapy (DAPT) and are more efficacious in the setting of patients with diabetes mellitus (DM). Patients with diabetes are particularly challenging in terms of PCI, as they tend to have worse outcomes compared with patients without diabetes.
In order to meet these clinical challenges, a novel DES was discussed: the Cre8TM (manufactured by CID Spa, member of Alvimedica Group), which features controlled polymer-free amphilimus formula elution from abluminal reservoirs on the surface of the stent. These unique and innovative features may enhance clinical outcomes in patient subsets, such as those with DM, and may represent a step forwards in treating these patients.
The publication of this article was supported by Alvimedica.